FDA approves first pill aimed at boosting female libido

August 19, 2015 byMatthew Perrone
FDA approves first pill aimed at boosting female libido
In this June 22, 2015, photo, a tablet of flibanserin sits on a brochure for Sprout Pharmaceuticals in the company's Raleigh, N.C., headquarters. The Food and Drug Administration on Tuesday, Aug. 18, 2015, approved the first prescription drug designed to boost sexual desire in women, a milestone long sought by a pharmaceutical industry eager to replicate the blockbuster success of impotence drugs for men. (AP Photo/Allen G. Breed)

The Food and Drug Administration has approved the first prescription drug designed to boost sexual desire in women, a milestone long sought by a pharmaceutical industry eager to replicate the blockbuster success of impotence drugs for men.

But stringent safety measures on the daily pill called Addyi mean it will probably never achieve the sales of Viagra, which has generated billions of dollars since the late 1990s.

The drug's label will bear a boxed warning—the most serious type—alerting doctors and patients to the risks of dangerously low blood pressure and fainting, especially when the pill is combined with alcohol. The same problems can occur when taking the drug with other commonly prescribed medications, including antifungals used to treat yeast infections.

"Patients and prescribers should fully understand the risks associated with the use of Addyi before considering treatment," said Dr. Janet Woodcock, director of the FDA's drug center, in a statement announcing the approval Tuesday.

Under an FDA-imposed safety plan, doctors will only be able to prescribe Addyi after completing an online certification process that requires counseling patients about Addyi's risks. Pharmacists will also need certification and will be required to remind patients not to drink alcohol while taking the drug.

Opponents of the drug say it's not worth the side effects, which also include nausea, drowsiness and dizziness. They point out that the FDA rejected the drug twice, in 2010 and 2013, due to these risks.

"This is not a drug you take an hour before you have sex. You have to take it for weeks and months in order to see any benefit at all," said Leonore Tiefer, a psychologist and sex therapist who organized a petition last month calling on the FDA to reject the drug.

Patients should stop taking the drug after eight weeks if they do not see any improvement, notes the FDA release.

Sprout Pharmaceutical's drug is intended to treat women who report emotional stress due to a lack of libido. Its approval marks a turnaround for the FDA, which previously rejected the drug twice due to lackluster effectiveness and side effects. The decision represents a compromise of sorts between two camps that have publicly feuded over the drug for years.

On one side, Sprout and its supporters have argued that women desperately need FDA-approved medicines to treat sexual problems. On the other side, safety advocates and pharmaceutical critics warn that Addyi is a problem-prone drug for a questionable medical condition.

Beginning with the drug's launch in mid-October, doctors who see patients complaining about a loss of sexual appetite will have a new option.

FDA approves first pill aimed at boosting female libido
In this June 22, 2015, photo, Sprout Pharmaceuticals CEO Cindy Whitehead works in her office in Raleigh, N.C. The Food and Drug Administration on Tuesday, Aug. 18, 2015, approved Sprout Pharmaceutical's first prescription drug designed to boost sexual desire in women, a milestone long sought by a pharmaceutical industry eager to replicate the blockbuster success of impotence drugs for men. (AP Photo/Allen G. Breed)

"Women are grasping, and I feel like we need to offer them something that acknowledges that, and that we can feel safe and comfortable with," said Dr. Cheryl Iglesia, a surgeon and official with the American Congress of Obstetricians and Gynecologists. Iglesia said she has occasionally resorted to prescribing testosterone creams to boost women's libido, a use not approved by the FDA.

The search for a pill to treat women's sexual difficulties has been something of a holy grail for the pharmaceutical industry. It was pursued and later abandoned by Pfizer, Bayer and Procter & Gamble, among others. But drugs that act on blood flow, hormones and other biological functions all proved ineffective.

Addyi, known generically as flibanserin, is the first drug that acts on brain chemicals that affect mood and appetite.

Women and their doctors will have to decide whether the drug's modest benefits warrant taking a psychiatric pill on a daily basis.

Company trials showed women taking the drug generally reported one extra "sexually satisfying event" per month, and scored higher on questionnaires measuring desire.

Tiefer and other critics said the FDA was pressured into approving the drug by a feminist-themed lobbying campaign funded by Sprout and other drugmakers.

"It's just a mishmash of politics and science and sex and money," Tiefer said.

The lobbying group, dubbed Even the Score, began publicizing the lack of drugs for female sexual dysfunction as a women's rights issue last year.

"Women deserve equal treatment when it comes to sex," the group states in an online petition to the FDA, which attracted more than 60,000 supporters. Women's groups, including the National Organization for Women, signed on to the effort, though it was funded by Sprout and other companies working on female sex drugs.

At an FDA meeting in June, more than 30 members of the public called for the drug's approval, frequently citing the Even the Score campaign. They vastly outnumbered speakers who spoke in opposition to the drug. At the meeting's conclusion, the panel of FDA advisers voted 18-6 to recommend approving the drug, with safety restrictions.

Read: Q&A: First pill approved to boost sex drive in women

Sprout declined to comment on how much it spent on the campaign.

For now, executives with the Raleigh, North Carolina-based company are setting modest expectations for Addyi, their first and only product. The company will focus its 200 sales representatives on promoting the drug to medical specialists.

"We will be small," CEO Cindy Whitehead said. "We will be specialty focused among the physicians who already have a familiarity with female sexual dysfunction."

Women with insurance can expect to pay between $30 and $75 per month for Addyi, depending on the terms of their coverage.

The FDA specifically approved the drug for premenopausal women with hypoactive sexual desire disorder, a lack of sexual appetite that causes distress.

Surveys estimate that 8 to 14 percent of women ages 20 to 49 have the condition, or about 5.5 to 8.6 million U.S. women. Because so many factors affect sexual appetite, there are a number of alternate causes doctors must rule out before diagnosing the condition, including relationship issues, medical problems, depression and mood disorders.

The diagnosis is not universally accepted, and some psychologists argue that low sex drive should not be considered a medical problem.

Explore further: US regulators to decide on 'female Viagra'

Related Stories

US regulators to decide on 'female Viagra'

August 18, 2015
US regulators are expected to decide Tuesday whether to approve a drug nicknamed the "female Viagra," which would be the first pill on the market to raise women's sex drive.

'Female Viagra' gets green light from US expert panel (Update)

June 4, 2015
A US advisory panel on Thursday urged regulators to approve a drug nicknamed the "female Viagra" because it could help increase women's sex drive.

US regulators to discuss 'female Viagra'

June 4, 2015
A drug nicknamed the "female Viagra" because it could help increase women's sex drive, will be discussed for a third time at a meeting of an advisory committee to US regulators Thursday.

FDA schedules meeting on twice-rejected female libido drug

May 7, 2015
The Food and Drug Administration will ask a group of outside medical experts next month to evaluate a much-debated experimental drug designed to boost sexual desire in women.

FDA panel backs female libido pill, under safety conditions

June 4, 2015
The drug industry's decade-spanning search for a female equivalent to Viagra took a major step forward Thursday, as government experts recommended approval for a pill to boost sexual desire in women.

FDA could approve first female libido pill soon

August 17, 2015
(HealthDay)—The U.S. Food and Drug Administration could soon approve a controversial drug aimed at boosting libido in women.

Recommended for you

Researchers publish study on new therapy to treat opioid use disorder

May 22, 2018
Better delivery of medications to treat opioid use disorder (OUD) is key to addressing the opioid crisis and helping the 2.6 million Americans affected by the disease.

Could nonprofit drug companies cut sky-high prices?

May 17, 2018
(HealthDay)—Generic prescription drugs should be cheap, but prices for some have soared in the United States in recent years. Now a group of U.S. hospitals thinks it has a solution: a nonprofit drug maker.

Fewer antibiotics for kids, but more ADHD drugs

May 15, 2018
(HealthDay)—American kids are taking fewer prescription medications these days—but certain drugs are being prescribed more than ever, a new government study finds.

Opioid makers' perks to docs tied to more prescriptions

May 14, 2018
Doctors who accept perks from companies that make opioid painkillers are more likely to prescribe the drugs for their patients, new research suggests.

Less is more when it comes to prescription opioids for hospital patients, study finds

May 14, 2018
In a pilot study published in JAMA Internal Medicine, Yale researchers significantly reduced doses of opioid painkillers given to hospital patients. By delivering the opioids with a shot under the skin or with a pill instead ...

Generic options provide limited savings for expensive drugs

May 7, 2018
Generic drug options did not reduce prices paid for the cancer therapy imatinib (Gleevec), according to a Health Affairs study released today in its May issue.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.